Inducible costimulatory molecule and its roles in tumor microenvironment

doi:10.3760/cma.j.issn.1673-422X.2015.07.010

Abstract

Abstract: Inducible costimulatory molecule (ICOS) is a member of the CD28 family, which can be expressed on the tumor tissues and immune cells in the tumor microenvironment. ICOS enhances its antitumor activity through participating in CD4+ T and CD8+ T cell immune response and enhancing the secretion of cytokines on the activated T cells and NK cells. While the curative effect of cytotoxic T lymphocyteassociated antigen4 (CTLA4) monoclonal antibody is relevant with CD4+ T cells expressing ICOS, which suggesting ICOS may become a novel antitumor therapeutic target in the future.

Key words: Immunity, Tumor microenvironment, Inducible costimulatory molecule

Wu Dongjuan, Hua Dong. Inducible costimulatory molecule and its roles in tumor microenvironment[J]. Journal of International Oncology, 2015, 42(7): 516-518.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. ［2］ PolyakK, Haviv I, Campbell IG. Coevolution of tumor cells and their microenvironment［J］. Trends Genet, 2009, 25(1): 30-38. ［3］ Oluwadara O, Giacomelli L, Brant X, et al. The role of the microenvironment in tumor immune surveillance［J］. Bioinformation, 2011, 5(7): 285-290. ［4］ Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T cell costimulator: a structurally and functionally related to CD28［J］. Nature, 1999, 397(6716): 263-266. ［5］ Yao S, Zhu Y, Zhu G, et al. B7h2 is a costimulatory ligand for CD28 in human［J］. Immunity, 2011, 34(5): 729-740. ［6］ Larimore K, Liang L, Bakkour S, et al. B7hexpressing dendritic cells and plasma B cells mediate distinct outcomes of ICOS costimulation in T celldependent antibody responses［J］. BMC Immunol, 2012, 13: 29. ［7］ MartinOrozco N, Li Y, Wang Y, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of Tregulatory cells［J］. Cancer Res, 2010, 70(23): 9581-9590. ［8］ Schreiner B, Wischhusen J, Mitsdoerffer M, et al. Expression of the B7related molecule ICOSL by human glioma cells in vitro and in vivo［J］. Glia, 2003, 44(3): 296-301. ［9］ Rudulier CD, McKinstry KK, AIYassin GA, et al. The number of responding CD4 T cells and the dose of antigen conjointly determine the TH1/TH2 phenotype by modulating B7/CD28 interactions［J］. J Immunol, 2014, 192(11): 5140-5150. ［10］ Chen XL, Cao CD, Kang AJ, et al. In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma［J］. World J Gastroenterol, 2003, 9(6): 1370-1373. ［11］ Baseggio L, TraverseGlehen A, Berger F, et al. CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic Tcell lymphoma［J］. Modern Pathology, 2011, 24(7): 993-1003. ［12］ Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy［J］. Blood, 2013, 121(5): 734-744. ［13］ Zhang Q, Wang H, Kantekure K, et al. Oncogenic tyrosine kinase NPMALK induces expression of the growthpromoting receptor ICOS［J］. Blood, 2011, 118(11): 3062-3071. ［14］ Chen H, Fu T, Suh WK, et al. CD4 T cells require ICOSmediated PI3K signaling to increase TBet expression in the setting of antiCTLA4 therapy［J］. Cancer Immunol Res, 2014, 2(2): 167-176. ［15］ Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory Tcells in multiple myeloma is contactdependent and antigenpresenting cellindependent［J］. PLoS One, 2012, 7(5): e35981. ［16］ He M, Wang Y, Shi WJ, et al. Immunomodulation of inducible costimulator (ICOS) in human cytokineinduced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction［J］. J Dig Dis, 2011, 12(5): 393-400. ［17］ Galicia G, Kasran A, Uyttenhove C, et al. ICOS deficiency results in exacerbated IL17 mediated experimental autoimmune encephalomyelitis［J］. J Clin Immunol, 2009, 29(4): 426-433. ［18］ Chen H, Liakou CI, Kamat A, et al. AntiCTLA4 therapy results in higher CD4+ICOShi T cell frequency and IFNgamma levels in both nonmalignant and malignant prostate tissues［J］. Proc Natl Acad Sci USA, 2009, 106(8): 2729-2734. ［19］ Bogunovic D, O′Neill DW, BelitskayaLevy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival［J］. Proc Natl Acad Sci USA, 2009, 106(48): 20429-20434. ［20］ Gousias K, von Ruecker A, Voulgari P, et al. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas［J］. J Neuroimmunol, 2013, 264(1-2): 84-90. ［21］ Harshman LC, Drake CG, Wargo JA, et al. Cancer immunotherapy highlights from the 2014 ASCO meeting［J］. Cancer Immunol Res, 2014, 2(8): 714-719. ［22］ Fan X, Quezada SA, Sepulveda MA, et al. Engagement of the ICOS pathway markedly enhances efficacy of CTLA4 blockade in cancer immunotherapy［J］. J Exp Med, 2014, 211(4): 715-725. ［23］ Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by antiCTLA4 therapy［J］. Cancer Res, 2011, 71(16): 5445-5454.

[1]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.
[2]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[3]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie. Research progress of myeloid-derived suppressor cells in tumor angiogenesis [J]. Journal of International Oncology, 2024, 51(1): 50-54.
[4]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[5]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei. Current status of research on exosomes in malignancies [J]. Journal of International Oncology, 2023, 50(8): 484-488.
[6]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[7]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[8]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy [J]. Journal of International Oncology, 2023, 50(3): 169-173.
[9]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[10]	Zhu Yi, Chen Jian. Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects [J]. Journal of International Oncology, 2023, 50(12): 729-733.
[11]	Xie Lulu, Ding Jianghua. Progress of immunotherapy-based strategy in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(11): 672-676.
[12]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[13]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[14]	Wu Jiayu, Liu Jiacheng. Research progress of radiomics toward lung adenocarcinoma manifesting as solitary ground glass nodule [J]. Journal of International Oncology, 2022, 49(8): 449-452.
[15]	Zhang Zishu, Wu Xinlin. Mechanism of action of lactic acid in tumor microenvironment and related treatment [J]. Journal of International Oncology, 2022, 49(6): 349-352.